{Reference Type}: Journal Article
{Title}: The new dual gastric inhibitory peptide/glucagon-like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?
{Author}: Papachristou S;Popovic DS;Papanas N;
{Journal}: Diabetes Metab Res Rev
{Volume}: 37
{Issue}: 8
{Year}: Nov 2021
{Factor}: 8.128
{DOI}: 10.1002/dmrr.3503
{Abstract}: Tirzepatide is a dual gastric inhibitory peptide/glucagon-like peptide 1 (GIP/GLP-1) receptor agonist formulated as a synthetic linear peptide, based on the native GIP sequence. It has a prolonged half-life of 5 days, which enables once-weekly dosing. Studies have hitherto demonstrated its superiority in achieving optimal glycaemic control and body weight management, as compared with various agents used in the treatment of type 2 diabetes mellitus (T2DM), including GLP-1 receptor agonists. Thus, it is expected to enrich our therapeutic armamentarium in T2DM. However, further experience, notably longer follow-up data and information on cardiovascular effects, is still needed.